MYOK - MyoKardia, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
58.6500
+3.6500 (+6.6364%)
As of 2:57PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close55.0000
Open55.7000
Bid58.6500 x 200
Ask58.9000 x 200
Day's Range54.5750 - 59.1500
52 Week Range10.8000 - 59.1500
Volume213,875
Avg. Volume409,124
Market Cap2.096B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7670
Earnings DateMar 12, 2018 - Mar 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.00
Trade prices are not sourced from all markets
  • Cramer's lightning round: Why I can't go down the path of...
    CNBC Videos5 months ago

    Cramer's lightning round: Why I can't go down the path of...

    Jim Cramer rattles off his take on callers' favorite stocks at lightning speed, including one struggling steel producer.

  • GlobeNewswire7 days ago

    MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...

  • GlobeNewswire7 days ago

    MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

    SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...

  • GlobeNewswirelast month

    MyoKardia Announces Appointment of Cynthia Ladd as General Counsel

    SOUTH SAN FRANCISCO, Calif., Jan. 19, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMT

    Q3 2017 MyoKardia Inc Earnings Call

  • SmarterAnalystlast month

    4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE)

    The company’s lead asset, Trilaciclib, is currently being evaluated in a number of settings as a tack-on to the standard of care in both front line and 2nd-3rd lines of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). CDK4/6 keeps cells in stasis, known as the G1 phase of the cell cycle, rendering it difficult to undergo cell division.

  • GlobeNewswire2 months ago

    MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...

  • MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017
    Capital Cube2 months ago

    MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MyoKardia, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Capital Cube3 months ago

    MyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : November 8, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives MyoKardia, Inc. a score of 71. Our analysis is based on comparing MyoKardia, Inc. with the following peers – OrganiGram Holdings Inc, Ohr Pharmaceutical, Inc., Oragenics, Inc. and OncoCyte Corp. (OGI-CA, OHRP-US, OGEN-US and OCX-US). Investment Outlook MyoKardia, Inc. has a fundamental score of 71 and has ... Read more (Read more...)

  • Myokardia Inc (MYOK) Q3:17 Update At First Glance
    SmarterAnalyst3 months ago

    Myokardia Inc (MYOK) Q3:17 Update At First Glance

    Shares of Myokardia Inc (NASDAQ:MYOK) are down nearly 3% Tuesday as investors digest the biotech firm's third-quarter financial results. The company reported Q3 EPS of $(0.42) in line with street consensus, and reflecting a total net loss for the quarter of $14.2 million. MyoKardia also provided an update on the company’s End-of-Phase 2 meeting with the FDA Division of Cardiovascular and Renal Products.  The meeting focused on MyoKardia’s proposed registration program for mavacamten (formerly MYK-461) in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM).  MyoKardia is incorporating guidance from the FDA on study design elements and plans to proceed with the pivotal Phase 3 trial, EXPLORER-HCM, and a long-term extension study, as the key remaining studies in the mavacamten registration program.  The company anticipates dosing the first patient in EXPLORER-HCM in the second quarter of 2018.  Between now and study start, the company plans to review the final trial design with the FDA.

  • MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017
    Capital Cube4 months ago

    MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MyoKardia, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Associated Press4 months ago

    MyoKardia reports 3Q loss

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed ...

  • MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : October 12, 2017
    Capital Cube4 months ago

    MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : October 12, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MyoKardia, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to MyoKardia, Inc. : October 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MyoKardia, Inc. Here are 5 ETFs with the largest exposure to MYOK-US. Comparing the performance and risk of MyoKardia, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Best Sector ETF of Q3 and its Top-Performing Stocks
    Zacks5 months ago

    Best Sector ETF of Q3 and its Top-Performing Stocks

    Inside the top performing stocks of top U.S.-focused ETF of Q3.

  • TheStreet.com5 months ago

    MyoKardia Unveils More Phase 2 Data on Heart Disease Treatment

    The South San Francisco, Calif. on Sept. 18 presented additional data from the first patient cohort of its Phase 2 study